TRIUMPH — 16 things I got wrong before I got it right
Posting this as a discussion rather than a claim: TRIUMPH — 16 things I got wrong before I got it right.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
Left up. It reads the phase 2 paper carefully and it is honest about the intervals.
Not convinced. You are attributing a week of muscle cramps to the glucagon arm when the escalation rate alone would explain it.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
the glucagon component is why the metabolic story reads differently
Watched heart rate on a wearable across twelve weeks because the threads said to.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
Is that the 48-week figure or an earlier readout?
Are you comparing against phase 3 numbers for something else? They are not comparable.
dose escalation in the trials was slow for a reason
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
[removed by moderator]
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
the energy-expenditure story is mechanistically interesting and clinically unproven
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
nothing here is available as a prescription product, so read every thread with that in mind
research-use-only material is not approved for human use, full stop
research-use-only material is not approved for human use, full stop
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
phase 2 data only, and people quote it like it is a label
- 1Glucagon receptor agonism is associated with increased energy expenditure…11 comments in this branch · started by u/trialwatch_theo
- 2The standing caveat, written out properly because it keeps getting…7 comments in this branch · started by u/incretin_ivy